Introduction
AIDS is characterized by numerous immunological abnormalities, alterations in lymphocyte populations, and immunosuppression with subsequent development of opportunistic infections (1) . Many of these changes can be attributed to alterations in mediator production including cytokines (2) and eicosanoids (3, 4) . Prostaglandins (PG) are one such group of mediators that are modulated in HIV infection (5, 6) . In patients with AIDS, serum levels of PGE 2 are significantly increased relative to serum levels of PGE 2 in normal controls (6) . Augmented levels of PG are also found in cerebral spinal fluid (CSF) of AIDS patients (7, 8) . Peripheral blood monocytes (PBM) and macrophages play multiple roles in primary HIV-1 infection as both producers of immune mediators and as reservoirs for the virus (9, 10) . In vitro production of PGE 2 and thromboxane B 2 by PBM from AIDS patients is increased relative to normal controls (11, 12). Experimental infection of human PBM with HIV-1 also results in increased production of PGE 2 relative to uninfected control cultures (13-16).
PG can be converted non-enzymatically to other compounds, including cyclopentenone PG (cyPG) (17). Primary PG, PGE 1 and PGE 2 can be converted to the cyPG, PGA 1 and PGA 2 respectively, in aqueous solution or plasma over 12 h (18) . It has been shown that cyPG have different biological activities from the primary PG. CyPG are actively incorporated into cells, independent of PG receptors, and are transferred to the nucleus. In the nucleus cyPG lead to cell cycle arrest at the G 1 phase, and inhibit the replication of a variety of viruses, including both 
MDM cultures
Blood was drawn from healthy donors using heparin as an anticoagulant and layered on Ficoll-Hypaque (density 1.077 g/ml) (Amersham, Arlington Heights, IL). After centrifugation at 20 °C for 45 minutes at 800 x g, plasma was aspirated, the interface layer harvested, and washed 2X with cold PBS (without Ca 2+ or Mg 2+ , 0.1% BSA). The cell pellet was resuspended to 2.5 x replacement) at intervals of 2-3 days. The monocytic cell line U1 is a clone of the cell line U937
and is latently infected with HIV-1 (33 
Measurement of HIV-1 replication
Reverse transcriptase (RT) assay: Samples (3 µl) were mixed with 12 µl RT assay buffer containing 1 µCi/ml 32 P dTTP. The reaction mixture was incubated at 37 °C for 2.5 hours. 3.5
µl of each sample was blotted on DEAE paper and air-dried. Blots were washed (with gentle agitation) three times in 2X SSC. Blots were then washed with 95% ethanol and air-dried (35).
Incorporation of 32 P dTTP was measured using the PhosphoImager system (Molecular Dynamics) (36).
RT-polymerase chain reaction (PCR) Protocol: MDM, U937 and U1 cell line were treated for RT assay (Figure 1 ). The inhibitory effect of PGA 1 and PGA 2 was dose-dependent. The addition of cyPG after HIV-1 infection was also effective in suppressing viral replication but to a lesser degree (data not shown). There was no significant decrease in cell viability between treatment groups (data not shown), as assessed by MTT assay.
CyPG Inhibit HIV-1 replication in U1 cells.
One mechanism by which cyPG could regulate HIV-1 replication is at the level of viral entry and fusion with the cell membrane. Furthermore, other investigators have shown that other PG can down-regulate the expression of CCR5, the HIV-1 co-receptor (47). Therefore, we examined the effect of cyPG on CCR5 expression. We determined that cyPG had no significant effect on CCR5 expression with the mean fluorescence index 48.8 ± 1.3 for untreated cells and 57.7 ± 10.5 for PGA 2 treated cells, n=3, p=ns. We next chose a cell type in which HIV-1 replication was fusion / entry independent. In this system, we determined that treatment of the latently infected monocytic cell line, U1 cells, with PGA 1 and PGA 2 , at a concentration of 10
the U1 cells suggest that the effect of PGA 1 and PGA 2 on viral replication was not likely to be at the fusion / entry of HIV-1, but at a post-integration level, e.g., gene regulation.
Synthetic PPARγ activators inhibit HIV-1 BAL replication in MDM.
Since Figure 3B ). This was also true at higher concentrations (data not shown).
Synthetic PPARγ activators inhibit HIV-1 replication in U1 cells.
Having demonstrated that the natural PPARγ agonists cyPG suppressed HIV-1 replication in U1 cells, we next examined the ability of the synthetic PPARγ agonist to suppress HIV-1 replication in the same cells. The PPARγ agonist ciglitazone inhibited HIV-1 replication in PMA-stimulated U1 cells, while even higher doses of the PPARα agonist WY-14643, had no effect ( Figure 4 ). There was no significant decrease in cell viability between treatment groups (data not shown), as assessed by MTT assay.
Natural and synthetic PPARγ agonists decrease HIV-1 mRNA levels.
Since cyPG and PPARγ agonists are able to block induction of HIV-1 from latency in the U1 model, we next wanted to determine whether the effect of PGA 1 and PGA 2 treatment was at the level of gene expression. Treatment of U1 cells with PGA 1 and PGA 2 decreased levels of HIV mRNA, as measured by RT-PCR, in parallel with the decrease in RT activity ( Figure 5A and 5B). Next we examined the effect of synthetic PPAR agonists on the levels of HIV mRNA in U1 cells. Ciglitazone, the PPARγ agonist, but not the PPARα agonist WY-14643, suppressed HIV mRNA levels ( Figure 5B ). These data strongly suggest that the effects of the natural and synthetic PPARγ agonists occur at the level of HIV gene expression.
PPARγ agonists inhibit HIV-1 promoter activity.
We PPARs are ligand inducible transcription factors that belong to the family of nuclear transcription factors. PPARα is expressed in freshly isolated PBM and is found in many tissues including the liver, heart, kidney, skeletal muscle, lung, and adipose tissue. PPARγ is expressed abundantly in adipose tissue, but also in skeletal muscle, liver, heart, and bone marrow stromal cells. PPARγ exists as 3 isomers, PPARγ1 being predominantly expressed in macrophages.
PPARγ is also expressed upon activation of PBM, and their differentiation into macrophages. There is a dearth of information on the effect of PPARγ on mRNA stability. The predominant effect of PPARγ is on transcriptional regulation. In the manuscripts that investigate the role of PPARγ on post-transcriptional regulation, there was no effect on mRNA stability (62, Mean data from an experiment performed in triplicate is shown. 
